Literature DB >> 19581764

[Pathology of nonalcoholic steatohepatitis].

Yoon-Mi Jeen1, So-Young Jin.   

Abstract

Nonalcoholic steatohepatitis (NASH), one of the NAFLDs (nonalcoholic fatty liver diseases), is regarded as a hepatic manifestation of metabolic syndrome. NASH can progress to cirrhosis, and possibly to hepatic malignancy. Currently, liver biopsy is the only reliable method of assessing the presence or absence of NASH and the stage of fibrosis. The finding of steatosis with evidence of hepatocyte injury such as inflammation, ballooning, degeneration, and/or fibrosis, is generally essential for making a diagnosis of NASH. However, its diagnostic criteria have not yet been established. The pathologic findings of NASH and related diseases, and the grading system currently in use are reviewed herein.

Entities:  

Mesh:

Year:  2009        PMID: 19581764     DOI: 10.3350/kjhep.2009.15.2.122

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  2 in total

1.  Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.

Authors:  Joanna M Lotowska; Maria E Sobaniec-Lotowska; Sylwia B Bockowska; Dariusz M Lebensztejn
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice.

Authors:  Sung Woo Kim; Wonhee Hur; Tian Zhu Li; Young Ki Lee; Jung Eun Choi; Sung Woo Hong; Kwang-Soo Lyoo; Chan Ran You; Eun Sun Jung; Chan Kun Jung; Taesun Park; Soo-Jong Um; Seung Kew Yoon
Journal:  Exp Mol Med       Date:  2014-04-25       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.